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This Table lists key protein targets in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common por-
tal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 [2].
Voriconazole is a ﬁrst-line antifungal agent for the treat-
ment of invasive aspergillosis. The major metabolic pathway
is by cytochrome P450 (CYP) 2C19, 3 A4 and 2C9. Pharmaco-
kinetics of voriconazole appear to be near linear in children
<12 years and nonlinear in children ≥12 years and adults [3].
Therapeutic drug monitoring (TDM) of voriconazole has
been recommended because of the large variability in drug
exposure and relative narrow therapeutic window [4].
Recently, in adults, it was shown that severe inﬂamma-
tion, reﬂected by C-reactive protein (CRP) value, was
associated with elevated voriconazole trough concentrations
[5–8]. This was explained by inﬂammatory stimuli leading to
downregulation of CYP isoenzymes, resulting in reduced
metabolism of voriconazole [9].
The aim of this study was to investigate if routinely
measured voriconazole concentrations in children were also
associated with inﬂammation, reﬂected by CRP value [6, 7].
In this retrospective study, paediatric patients treated with
voriconazole between January 2005 and January 2015 at the
UniversityMedical Centre, Groningen, theNetherlands, were
eligible for inclusion. Patients with a steady-state voricona-
zole trough concentration and a CRP value measured on the
same day were included. Exclusion criteria were concomitant
use of CYP inducers/inhibitors and relatively low (<7.5 mg/
kg/day) or high (>12.5 mg/kg/day) voriconazole dosage to
avoid bias due to extreme dosing. Only the ﬁrst eligible data
set was selected from each patient to ensure that each patient
contributed equally to the ﬁnal data set.
TDM of voriconazole is routinely performed for all
children in our hospital using a validated assay (within-run
coefﬁcient of variation 1.9–2.3%, between-run coefﬁcient of
variation 0.0–3.1%, limit of quantiﬁcation 0.1 mg/l) [10].
This assay is routinely evaluated by international proﬁciency
testing [11].
Medical data were collected from the medical chart. This
study was evaluated by the local ethics committee and the
need for written informed consent was waived due to its
retrospective nature (IRB-2013-491).
Patients were divided in two groups based on their age [3]:
group 1 (<12 years) and group 2 (≥12 years). To investigate
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the inﬂuence of inﬂammation on voriconazole trough con-
centrations a Mann–Whitney U test and a box and whisker
plot were performed with CRP values categorized in low to
moderately high (0–150 mg/l) and high (>150 mg/l) concen-
trations [12].
Statistical tests were performed using SPSS, version 20.0
(IBM Corporation, Armonk, New York).
Twenty-seven paediatric patients were included in this
study, of which 11 children in group 1 (median age 4 years,
interquartile range [IQR]: 2–6 years) and 16 children in
group 2 (median age 15 years, IQR: 13–17 years). Patient
characteristics, including underlying disease, voriconazole
trough concentration and CRP value were similar between
both groups.
In Group 1, no signiﬁcant difference (P = 0.682) in
voriconazole trough concentration was observed between
children with CRP values 0–150 mg/l (2.6 mg/l, IQR:
0.9–4.3 mg/l; n = 8) and children with CRP values >150 mg/l
(3.3mg/l, IQR: 2.7–3.3mg/l; n = 3). In Group 2, a signiﬁcantly
higher (P = 0.027) voriconazole trough concentration was
found in children with CRP values >150 mg/l (5.8, IQR:
4.2–9.1 mg/l; n = 5) compared to children with CRP values
0–150 mg/l (2.2 mg/l, IQR: 0.9–4.9 mg/l; n = 11). See
Figure 1.
All groups received similar voriconazole doses based on
mg/kg body weight (Group 1: P = 0.470 and Group 2:
P = 0.817).
This retrospective analysis showed that inﬂammation,
reﬂected by CRP value, seems associated with higher
voriconazole trough concentrations in children ≥12 years;
however, the effect is less distinct compared to adult
patients [5]. For children <12 years no effect of
inﬂammation on voriconazole trough concentrations was
observed.
Dote and colleagues [8] showed that coadministration of
glucocorticoids an inﬂammation, reﬂected by CRP and
hypoalbuminaemia, were associated with voriconazole
clearance. Due to limited use of glucocorticoids and limited
determination of albumin in our population, we were not
able to investigate these other covariables in our study.
Spriet and colleagues [4] were not able to demonstrate an
association between voriconazole trough concentrations and
CRP in children. However, their results should be interpreted
prudently, because of the smaller patient cohort (n = 10). Fur-
thermore, no distinction was made between younger and
older children [4].
A potential explanation could be the difference in liver
microsomes, CYP2C19, CYP3A4 and ﬂavin-containing
mono-oxygenase 3 (FMO3), between children aged 2–
10 years and adults. The main metabolite of voriconazole,
voriconazole N-oxide, was formed three-fold quicker in liver
microsomes from children. It thus seems that FMO3 and
CY2C19 have a higher metabolic activity in young children
as compared to adults, since expression is not signiﬁcantly
different in both populations [13]. As the metabolic activity
of CYP2C19 is probably higher in younger children, a de-
crease in expression due to inﬂammation will be less likely
to have impact on voriconazole metabolism.
The main limitation of our study is its retrospective na-
ture. However, we used strict inclusion criteria to avoid bias
by other factors that could have a signiﬁcant impact on
voriconazole trough concentrations, such as non-steady-
state concentrations and extreme dosages.
In conclusion, inﬂammation as reﬂected by CRP values, is
associated with higher voriconazole trough concentrations in
children ≥12 years but not in children <12 years. The CRP
value may be helpful in TDM of voriconazole during severe
infection.
Figure 1
Difference in voriconazole trough concentration in relation to C-reactive protein (CRP_. Box (median and 25th and 75th percentiles) and
whisker (5th and 95th percentiles) plots of voriconazole trough concentrations in children aged <12 years (left panel) and children aged
≥12 years (right panel) with no to moderate inﬂammation and with severe inﬂammation. For children aged ≥12 years a signiﬁcant difference
in voriconazole trough concentration was found between children with low to moderately high CRP concentration and high CRP
concentration (P = 0.027)
Letter to the Editor
Br J Clin Pharmacol (2017) 83 678–680 679
Competing Interests
There are no competing interests to declare.
References
1 Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ,
Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY
in 2016: towards curated quantitative interactions between 1300
protein targets and 6000 ligands. Nucl Acids Res 2016; 44:
D1054–D1068.
2 Alexander SPH, Fabbro D, Kelly E, Peters JA, Benson HE,
Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16:
Enzymes. Br J Pharmacol 2015; 172: 6024–109.
3 Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic
analysis of voriconazole plasma concentration data from pediatric
studies. Antimicrob Agents Chemother 2009; 53: 935–44.
4 Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans
M, et al. Voriconazole plasma levels in children are highly
variable. Eur J Clin Microbiol Infect Dis 2011; 30: 283–7.
5 van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges
DR, van der Werf TS, et al. Inﬂammation is associated with
voriconazole trough concentrations. Antimicrob Agents
Chemother 2014; 58: 7098–101.
6 Encalada Ventura MA, Span LF, van den Heuvel ER, Groothuis
GM, Alffenaar JW. Inﬂuence of inﬂammation on voriconazole
metabolism. Antimicrob Agents Chemother 2015; 59: 2942–3.
7 Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG,
van den Heuvel ER, Uges DR, et al. Longitudinal analysis of the
effect of inﬂammation on voriconazole trough concentrations.
Antimicrob Agents Chemother 2016; 60: 2727–31.
8 Dote S, Sawai M, Nozaki A, Naruhashi K, Kobayashi Y, Nakanishi
H. A retrospective analysis of patient-speciﬁc factors on
voriconazole clearance. J Pharm Health Care Sci 2016; 2: 10. doi:
10.1186/s40780-016-0044-9. eCollection 2016.
9 Morgan ET. Impact of infectious and inﬂammatory disease on
cytochrome P450-mediated drug metabolism and
pharmacokinetics. Clin Pharmacol Ther 2009; 85: 434–8.
10 Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B,
Kosterink JG, Uges DR. Method for therapeutic drug
monitoring of azole antifungal drugs in human serum using
LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci
2010; 878: 39–44.
11 Lempers VJ, Alffenaar JW, Touw DJ, Burger DM, Uges DR,
Aarnoutse RE, et al. Five year results of an international
proﬁciency testing programme for measurement of antifungal
drug concentrations. J Antimicrob Chemother 2014; 69: 2988–94.
12 Hengst JM. The role of C-reactive protein in the evaluation and
management of infants with suspected sepsis. Adv Neonatal Care
2003; 3: 3–13.
13 Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr,
Thakker DR. In vitro hepatic metabolism explains higher clearance
of voriconazole in children versus adults: role of CYP2C19 and
ﬂavin-containing monooxygenase 3. Drug Metab Dispos 2010;
38: 25–31.
Letter to the Editor
680 Br J Clin Pharmacol (2017) 83 678–680
